

2ND ANNUAL SUMMIT ON PRACTICAL AND EMERGING TRENDS IN

Lymphoid Malignancies & Multiple Myeloma

THE
FAIRMONT CHÂTEAU
WHISTLER

BRITISH COLUMBIA
CANADA

March 11-15
2015

Chairs

JENNIFER BROWN, MD, PHD

Dana-Farber Cancer Institute
Boston, MA

JOHN BYRD, MD

The Ohio State University
Columbus, OH

SUNDAR JAGANNATH, MD

Mount Sinai Hospital
New York, NY

SAGAR LONIAL, MD

Emory University
Atlanta, GA

WYNDHAM WILSON, MD, PHD

National Cancer Institute, NIH
Bethesda, MD



FOR MORE INFORMATION GO TO:

WWW.OMIONC.COM/WHISTLER

Lymphoid Malignancies & Multiple Myeloma

Wednesday - Sunday

March 11-15
2015



Overview

The 2nd Annual Summit on Practical and Emerging Trends in Lymphoid Malignancies and Multiple Myeloma will focus on the clinical and practical changes that will occur over the next 2 to 5 years. The summit is formatted to better foster discussion and debate on the evolution of treatment approaches, featuring individual patient populations through case-based discussions. Compelling data on the effects of novel strategies, such as chimeric antigen receptor-expressing T cells, new targets, and next-generation antibody therapy, have led to an explosion of new information and agents in development for patients with hematologic malignancies. How these new agents will be incorporated into clinical care will become an ever-increasing challenge for community oncologists as they treat the individual patient. The Summit on Practical and Emerging Trends in Lymphoid Malignancies and Multiple Myeloma assembles translational researchers, clinical researchers, and key community oncologists to address and meet the challenges of this rapidly developing area of oncology.

Who Should Attend?

This scientific summit is geared primarily towards hematologists and medical oncologists engaged in the diagnosis and treatment of patients with hematologic malignancies. Other health care professionals and researchers in the oncology field are also welcomed.

Key Objectives

CLL KEY TOPICS

- Evolution of care in CLL
- Approaches to high-risk patient populations
- Targeting B-cell signaling in CLL
- Next-generation CD-20 antibodies
- Combination strategies for the next generation of agents
- Emerging targets in CLL
- New technologies in CLL
- Special patient populations in CLL
- Is MRD important in CLL?

LYMPHOMA KEY TOPICS

- Evolution of chemo-immunotherapy in NHL
- Advances in the biology of DLBCL
- Advances in the therapeutic approach to mantle cell lymphoma
- Immunotherapeutic approaches to Hodgkin lymphoma
- Controversies in the treatment of indolent NHLs
- New advances in the genomic evolution of NHL
- Unique targets in NHL
- Novel therapeutic approaches to B-cell malignancies
- New targets for T-cell malignancies

MYELOMA KEY TOPICS

- Recent advances in the care of multiple myeloma
- Controversies in the care of multiple myeloma
- Personalized approaches to the treatment of myeloma
- Novel agents in development for multiple myeloma
- Emerging treatment paradigm in multiple myeloma
- MRD in myeloma and the role in new therapies
- New technologies on the horizon
- Advances in the genomics in myeloma

Faculty

Jeremy Abramson, MD

Assistant Professor, Department of Medicine
Harvard Medical School
Clinical Director, Lymphoma Program
Massachusetts General Hospital
Boston, MA

Jacqueline Barrientos, MD

Assistant Professor of Medicine
Hofstra North Shore-LIJ School of Medicine
New Hyde Park, NY

William Bensinger, MD

Professor of Medicine
Fred Hutchinson Cancer Research Center
Seattle, WA

James Berenson, MD

President and CEO,
James R. Berenson, MD, Inc
Medical & Scientific Director - Institute for
Myeloma & Bone Cancer Research
West Hollywood, CA

Leif Bergsagel, MD

Professor of Medicine
Mayo Clinic
Scottsdale, AZ

Jennifer Brown, MD, PhD

Associate Professor of Medicine
Director, CLL Center
Dana-Farber Cancer Institute
Boston, MA

John Byrd, MD

Professor of Internal Medicine and Medicinal
Chemistry
D. Warren Brown Chair of Leukemia Research
Director, Division of Hematology
The Ohio State University
Comprehensive Cancer Center
Columbus, OH

Adam Cohen, MD

Assistant Professor of Medicine
University of Pennsylvania
Abramson Cancer Center
Philadelphia, PA

Steven Coutre, MD

Professor of Medicine
Stanford University School of Medicine
Stanford, CA

Alexey Danilov, MD, PhD

Assistant Professor of Medicine
Oregon Health and Science University
Knight Cancer Institute
Portland, OR

Sven De Vos, MD, PhD

Associate Professor of Medicine
Director, Lymphoma Program
University of California, Los Angeles
Jonsson Comprehensive Cancer Center
Santa Monica, CA

Kieron Dunleavy, MD

Staff Clinician, Lymphoid Malignancies Branch
National Cancer Institute
Center for Cancer Research
Bethesda, MD

Yvonne Efebera, MD

Assistant Professor of Internal Medicine
The Ohio State University
Comprehensive Cancer Center
Columbus, OH

Alessandra Ferrajoli, MD

Associate Professor, Department of Leukemia
The University of Texas
MD Anderson Cancer Center
Houston, TX

Rafael Fonseca, MD

Professor of Medicine
Chair of the Department of Medicine
Mayo Clinic
Scottsdale, AZ

Nathan Fowler, MD

Associate Professor of Medicine
Lead, New Drug Development Group
Co-Director, Clinical and Translational
Research Program
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Randy Gascoyne, MD

Research Director, Lymphoid Cancers Center
BC Cancer Agency
Vancouver, BC, Canada

Sergio Giralt, MD

Chief, Adult Bone Marrow Transplant Service
Melvin Berlin Family Chair in Multiple
Myeloma
Memorial Sloan-Kettering Cancer Center
New York, NY

Brian Hill, MD, PhD

Assistant Professor
Cleveland Clinic
Taussig Cancer Institute
Cleveland, OH

Sundar Jagannath, MD

Director, Multiple Myeloma Program
Professor of Medicine
Mount Sinai Hospital
New York, NY

Jeffrey Jones, MD, MPH

Associate Professor of Medicine
Section Chief, CLL/HCL Clinical Research
Program
The Ohio State University
Comprehensive Cancer Center
Columbus, OH

Efstathios Kastritis, MD

Assistant Professor
National and Kapodistrian University of
Athens
Athens, Greece

Neil Kay, MD

Professor of Medicine
Mayo Clinic
Rochester, MN

Thomas Kipps, MD, PhD

Evelyn and Edwin Tasch Chair in
Cancer Research
Professor of Medicine
Deputy Director, Research Operations
UC San Diego
Moore's Cancer Center
La Jolla, CA

Faculty

CONTINUED

Shaji Kumar, MD

Professor of Medicine
Mayo Clinic
Rochester, MN

Alexander Lesokhin, MD

Assistant Member
Memorial Sloan-Kettering Cancer Center
New York, NY

Sagar Lonial, MD

Professor
Vice Chair of Clinical Affairs
Emory University
Winship Cancer Institute
Atlanta, GA

Lawrence Lum, MD, DSc

Professor of Medicine, Immunology and Microbiology
Scientific Director, BMT & Immunotherapy
Wayne State University
Karmanos Cancer Institute
Detroit, MI

David Miklos, MD

Medical Director of Stanford Cellular Therapeutics and Transplantation Laboratory
Stanford University
Stanford, CA

Sattva Neelapu, MD

Associate Professor
Director of Laboratory and Translational Research
The University of Texas
MD Anderson Cancer Center
Houston, TX

Yasuhiro Oki, MD

Assistant Professor
The University of Texas
MD Anderson Cancer Center
Houston, TX

Anders Österborg, MD, PhD

Professor of Oncology
Karolinska University Hospital
Stockholm, Sweden

John Pagel, MD, PhD

Associate Professor of Hematology & Oncology
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, WA

Antonio Palumbo, MD

Chief, Myeloma Unit of the Department of Oncology, Section of Hematology
University of Torino
Torino, Italy

Jae Park, MD

Attending Physician, Leukemia Service
Memorial Sloan-Kettering Cancer Center
New York, NY

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital
Newton, MA

Charles Schiffer, MD

Professor of Medicine and Oncology
Leader, Multidisciplinary Leukemia/Lymphoma Group
Barbara Ann Karmanos Cancer Institute
Detroit, MI

Emma Scott, MD

Assistant Professor of Medicine
Director of the Myeloma and Amyloid Program
Oregon Health and Science University
Knight Cancer Institute
Portland, OR

Jatin Shah, MD

Assistant Professor
The University of Texas
MD Anderson Cancer Center
Houston, TX

Andrei Shustov, MD

Associate Professor of Medicine
Chief, T-cell Lymphoma Program
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, WA

David Siegel, MD, PhD

Chief, Myeloma Division
Hackensack University Medical Center
John Theurer Cancer Center
Hackensack, NJ

Stephen Spurgeon, MD

Assistant Professor of Medicine
Section Head Hematologic Malignancies
Oregon Health & Science University
Knight Cancer Institute
Portland, OR

Keith Stewart, MBChB, MBA

Professor of Medicine
Mayo Clinic
Scottsdale, AZ

David Straus, MD

Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, NY

John Timmerman, MD

Associate Professor Medicine
University of California, Los Angeles
Jonsson Comprehensive Cancer Center
Los Angeles, CA

Steven Treon MD, PhD

Director, Bing Center for Waldenström's Research
Associate Professor
Dana-Farber Cancer Institute
Boston, MA

Ravi Vij, MD

Associate Professor
Washington University in St. Louis
Siteman Cancer Center
St. Louis, MO

Michael Wang, MD

Professor of Medicine
The University of Texas
MD Anderson Cancer Center
Houston, TX

Adrian Wiestner, MD, PhD

Senior Investigator and Attending Physician
National Heart, Lung, and Blood Institute
National Institutes of Health
Bethesda, MD

Michael Williams, MD

Chief, Hematologic Malignancies Section
Byrd S. Leavell Professor of Medicine, Hematology and Oncology
University of Virginia, School of Medicine
Charlottesville, VA

Wyndham Wilson, MD, PhD

Chief, Lymphoma Section, Lymphoid Malignancies Branch
National Cancer Institute, NIH
Bethesda, MD

Jeffrey Zonder, MD

Associate Professor
Wayne State University
Karmanos Cancer Institute
Detroit, MI

Emerging Agents Breakout Sessions

10:00 AM - 12:00 PM

March 12: New Antibodies in Development in Hematologic Malignancies**March 13: Novel Downstream Signaling Inhibitors in Hematologic Malignancies****March 14: Novel Approaches: Epigenetics, ADCs, and Cellular-based Therapy**

Agenda

PLENARY SESSION*Wednesday, March 11*

12:00 PM Registration

4:30 PM Welcome and Introduction

EVENING SESSION**Setting the Stage**4:45 PM How do I treat CLL in 2015? *John Byrd*5:00 PM How do I treat DLBCL in 2015? *Wyndham Wilson*5:15 PM How do I treat MM in 2015? *Sundar Jagannath*5:30 PM How do I treat Waldenström's macroglobulinemia in 2015? *Steven Treon*5:45 PM How do I treat Hodgkin disease in 2015? *David Straus*

6:00 PM Discussion

6:15 PM Break

Setting the Stage6:30 PM How will I treat CLL in 2020? *Steven Coutre*6:45 PM How will I treat DLBCL in 2020? *Michael Williams*7:00 PM How will I treat MM in 2020? *Sagar Lonial*7:15 PM How will I treat AML in 2020? *Charles Schiffer*

7:30 PM Discussion

8:00 PM Adjourn

Sponsored wine and cheese reception

*Thursday, March 12***MORNING SESSION****Keynote Address**7:00 AM Advances in the understanding of the biology of CLL *Thomas Kipps***MORNING SESSION (continued)****CLL: State of the Art Plenary Session**7:15 AM Current clinical data of ibrutinib in CLL *Jennifer Brown*7:30 AM Impact of combining CD-20 mAb and idelalisib in CLL *John Pagel*7:45 AM Targeting high risk patients with del 17p *TBD*8:00 AM Key populations: Approaches to the elderly patients *Neil Kay*

8:15 AM Discussion

8:45 AM Break

Targeting Apoptosis9:00 AM Overcoming the challenges in targeting apoptotic pathways *Michael Williams*9:15 AM Clinical data and ongoing trials with BCL-2 inhibitors *Jacqueline Barrientos*

9:30 AM Discussion

10:00 AM Breakout Session

4:00 PM DAVA Research Consortia Meeting

EVENING SESSION**Practical Considerations**5:00 PM Second-generation CD-20 antibodies in CLL: What is the role in the B-cell signaling inhibitor era? *Anders Österborg*5:15 PM New ways to assess tumor burden in CLL/SLL *Adrian Wiestner*5:30 PM Mechanism of resistance to B-cell signaling inhibitors *Jeffrey Jones*

Debate: Is there a role for MRD in CLL?

5:45 PM Response: No *Steven Coutre*6:00 PM Response: Yes *David Miklos*

6:15 PM Discussion

6:30 PM Break

Emerging Toxicities of Novel Targets6:45 PM BTK inhibitors (including ibrutinib) *Jennifer Brown*7:00 PM PI3-kinase inhibitors (including idelalisib) *Jacqueline Barrientos*7:15 PM BCL-2 inhibitors (including venetoclax) *Stephan Spurgeon*7:30 PM CAR-T cell therapy in CLL the MSKCC experience *Jae Park*7:45 PM How do we convert chronic disease to a curable disease? *Jeffrey Jones*

8:00 PM Sponsored dinner

Agenda

PLENARY SESSION

Friday, March 13

MORNING SESSION

Hodgkin Disease: State of the Art Plenary Session

7:00 AM	New developments in Hodgkin disease biology	<i>Randy Gascoyne</i>
7:15 AM	Current state of the art in Hodgkin disease	<i>David Straus</i>
7:30 AM	Immune checkpoint inhibitors in Hodgkin disease	<i>Alexander Lesokhin</i>
7:45 AM	Brentuximab vedotin: Evolving role in CD-30 positive malignancies	<i>Andrei Shustov</i>
8:00 AM	Break	

DLBCL: State of the Art Plenary Session

8:15 AM	Understanding the mutational landscape of DLBCL	<i>Brian Hill</i>
8:30 AM	Current understanding of double hit lymphomas	<i>Kieron Dunleavy</i>
8:45 AM	Grey zone lymphoma	<i>Jeremy Abramson</i>
9:00 AM	Immune checkpoint inhibitors in DLBCL	<i>John Timmerman</i>
9:15 AM	Discussion	
9:45 AM	Break	

10:00 AM Breakout Session

4:00 PM DAVA Research Consortia Meeting

EVENING SESSION

Myeloma: State of the Art Plenary Session

5:00 PM	Genomic landscape of multiple myeloma: What have we learned?	<i>Leif Bergsagel</i>
5:15 PM	New staging classification of myeloma	<i>Antonio Palumbo</i>
5:30 PM	Clinical activity of CD-38 mAb in r/r myeloma	<i>Sagar Lonial</i>
5:45 PM	Targeting SLAMF-7 in r/r myeloma	<i>Ravi Vij</i>
6:00 PM	New pathways targeted in r/r myeloma	<i>Keith Stewart</i>
6:15 PM	Break	

New Strategies for Newly Diagnosed Myeloma

6:30 PM	Newer combinations to optimize cytoinduction in newly diagnosed myeloma	<i>Shaji Kumar</i>
6:45 PM	Ongoing trials with elotuzumab in myeloma	<i>Rafael Fonseca</i>
7:15 PM	Ongoing trials with daratumumab in myeloma	<i>Sagar Lonial</i>
Debate:	Can we cure myeloma without a transplant?	
7:45 PM	Response: No	<i>Sergio Giralt</i>
8:00 PM	Response: yes	<i>David Siegel</i>

8:15 PM Adjourn

Saturday, March 14

MORNING SESSION

MCL: Evolution of Care

7:00 AM	Advances in the understanding of biology of MCL	<i>Michael Williams</i>
7:15 AM	Ibrutinib in MCL: Changing the current treatment paradigm	<i>Stephan Spurgeon</i>
7:30 AM	Newer drugs in MCL (including cyclin D antagonists)	<i>Michael Wang</i>

New Targets for DLBCL & PTCL

7:45 AM	Targeting BTK in non-GCB DLBCL	<i>Wyndham Wilson</i>
8:00 AM	Immunotherapy targets in NHL	<i>Nathan Fowler</i>
8:15 AM	Peripheral T-cell lymphoma: Rationale for targeted approach	<i>Yasubiro Oki</i>
8:30 AM	Discussion	
8:45 AM	Break	

New Approaches to Indolent Lymphoma

9:00 AM	Rational combinations with B-cell signaling inhibitors	<i>John Timmerman</i>
9:15 AM	PD-1 and other immunomodulatory therapy in FL	<i>Sattva Neelapu</i>
9:30 AM	Targeting BCL-2 in low-grade NHL	<i>Sven De Vos</i>
9:45 AM	Discussion	
10:00 AM	Break	

10:00 AM Breakout Session

4:00 PM DAVA Research Consortia Meeting

EVENING SESSION

Special Populations

5:00 PM	Myeloma in the octogenarians: Disease characteristics and clinical outcomes in the era of modern anti-myeloma therapy	<i>Efstathios Kastritis</i>
5:15 PM	Patient selection in auto transplant for MM	<i>William Bensinger</i>
5:30 PM	Effect of timing and duration of maintenance lenalidomide in myeloma patients after autologous stem cell transplantations	<i>Yvonne Efebera</i>
5:45 PM	Pomalidomide: Why is it active in IMiD failures?	<i>James Berenson</i>
6:00 PM	Discussion	
6:15 PM	Break	

New Therapies for MM

6:30 PM	New data with carfilzomib & oprozomib	<i>Ravi Vij</i>
6:45 PM	Ixazomib, an oral proteasome inhibitor, in MM and amyloidosis	<i>Adam Cohen</i>
7:00 PM	Phase III data with panbinostat in MM	<i>Sagar Lonial</i>
7:15 PM	Amyloidosis: Future approaches	<i>Jeffrey Zonder</i>
7:30 PM	Case-based discussion	

8:00 PM Adjourn

Agenda

PLENARY SESSION

Sunday, March 15

MORNING SESSION

A Look to the Future

7:00 AM Oral Abstract Presentations *10 presenters*

Panel discussions on drug development in hematologic malignancies

8:00 AM Targeting the B-cell: What comes next? *Byrd /Ghia/Wiestner/Williams/Wilson*8:30 AM Innovative clinical trial design in hematologic malignancies *Coutre/Jagannath/Kipps/Lonial/Stewart*

9:00 AM Adjourn

Agenda

BREAKOUT SESSIONS

Thursday, March 12, 2015

BREAKOUT SESSION

New Antibodies in Development in Hematologic Malignancies

10:00 AM Enhanced IgG hexamerization mediates efficient C1q docking and more rapid and substantial complement-dependent cytotoxicity; preclinical proof of concept *Frank Beurskens (Genmab)*10:15 AM Development of novel bispecific antibodies *Bassil Dabiyat (Xencor)*10:30 AM Bi-specific antibodies in lymphoma *Lawrence Lum*10:45 AM DARTs *Jon Wigginton (Macrogenics)*11:00 AM Current development of SAR650984 in MM *TBD (Sanofi)*11:15 AM Targeting CD-37 in CLL *John Byrd*

11:30 AM Discussion

11:45 AM Adjourn

BREAKOUT SESSIONS (continued)

Friday, March 13, 2015

BREAKOUT SESSION

Novel Downstream Signaling Inhibitors in Hematologic Malignancies

10:00 AM Targeting duvelisib in CLL *David Roth (Infinity)*10:15 AM PNT2258 in DLBCL: A novel BCL-2 inhibitor *Richard Messmann (ProNAi)*10:30 AM Targeting the MyD88 L265P mutation in DLBCL with a TLR7/9 inhibitor *Lou Brenner (Idera)*10:45 AM Development of a CXCL12/SDF-1 inhibitor in myeloma *Kai Riecke (Noxxon)*11:00 AM Selective inhibitor of nuclear export: Selinexor (KPT-330) *John Byrd*11:15 AM Targeting Raf inhibitors in hairy cell leukemia *Jae Park*11:30 AM CNS DLBCL: Trial of ibrutinib and novel chemotherapy (TEDDIR) *Kieron Dunleavy*

11:45 AM Discussion

12:00 PM Adjourn

Saturday, March 14, 2015

BREAKOUT SESSION

Novel Approaches: Epigenetics, ADCs, and Cellular-based Therapy

10:00 AM CAR-T therapy: Bringing advanced technology to the clinic *David Chang (Kite Pharma)*10:15 AM Polatuzumab vedotin (αCD79b ADC) development in NHL *Michael Wenger (Genentech)*10:30 AM Ricolinostat development in myeloma *Noopur Raje*10:45 AM Mocetinostat development in NHL *Isan Chen (Mirati)*11:00 AM CUDC-907, a dual inhibitor of histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) enzymes *Jaye Viner (Curis)*11:15 AM Innovated diagnostic tool in myeloma *James Berenson*11:30 AM Phase I study update of the novel Pan-Pim kinase inhibitor LGH447 in patients with r/r MM *Shaji Kumar*11:45 AM OTX015: Novel BET inhibitor in hematologic malignancies *Arun Balakumaran (Merck)*

12:00 PM Adjourn

Agenda

DAVA RESEARCH CONSORTIA MEETING

Thursday, March 12, 2015

4:00 PM Ibrutinib in CLL & MCL *Janssen*

4:30 PM Nivolumab in hematologic malignancies *BMS*

Friday, March 13, 2015

4:00 PM Daratumumab: Development in multiple myeloma *Janssen*

4:30 PM Elotuzumab: Development in multiple myeloma *BMS*

Saturday, March 14

4:00 PM Development of a third generation CD-20 antibody *Mentrik*

REGISTRATION FORM

Registration fees include refreshment breaks, working lunch, and syllabus materials.

First Name _____ Middle Initial _____ Last Name _____

Credentials: _____ ☐ Physician ☐ Fellow ☐ PA-C ☐ PhD ☐ Pharmacist

Mailing Address _____

Suite _____ City _____ State _____ Postal/Zip Code _____

Phone Number _____ Fax _____

E-mail _____

(your confirmation will be sent via e-mail.)

☐ Check here if you have any special dietary needs, please specify _____

Please complete the registration form and mail it with your payment to the address below, or visit www.regonline.com/whistler2015 to register online. Checks and credit cards are accepted. To register by phone or fax, please call (214) 451-4517 or fax (214) 889-7070 (credit cards only). Please make checks payable to Dava Oncology, LP. All payments must be made by a draft on a United States bank.

Choose one of the following options:

Early Registration (ends Feb 6)

☐ MD \$399.00

☐ RN/ PharmD \$299.00

After Feb 6

☐ MD \$499.00

☐ RN/ PharmD \$399.00

Payment can be made by:

☐ Check ☐ VISA ☐ MasterCard ☐ Discover ☐ American Express

Name as It Appears on Credit Card _____

Signature _____

Card Number _____ Expiration Date _____

Security Code _____

(On back [front if American Express] of credit card)

Billing Address of Card (if different from above; zip code required):

Street _____ City _____ State _____ Zip _____

Oncology Meeting Innovations fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this activity is in need of accommodations, please notify us in order to receive service, please call (214) 451-4517.

Please mail payments or inquires to:

Oncology Meeting Innovations

5420 Lyndon B Johnson Fwy

Suite 410

Dallas, TX 75240

Fax: (214) 889-7070

3 WAYS TO REGISTER

- 1.) Go to our web site:
www.regonline.com/whistler2015
- 2.) Call our office :
p: (214) 451-4517
- 3.) Complete the registration form and mail it or fax with your payment to the address below
(Checks and credit cards are accepted.)

f: (214) 889-7070

Oncology Meeting Innovations
Lincoln Center 2
5420 Lyndon B Johnson Fwy
Suite 410
Dallas, TX 75240

Please make checks payable to
Dava Oncology, LP.

Dava Oncology, LP fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this activity is in need of accommodations, please notify us in order to receive service.



Lymphoid Malignancies & Multiple Myeloma

THREE WAYS TO REGISTER

1.) Go to our web site:
www.regonline.com/whistler2015

2.) Call our office :
p: (214) 451-4517

3.) Complete the registration form
and mail it or fax with your payment
to the address below
(Checks and credit cards are
accepted.)

f: (214) 889-7070

Oncology Meeting Innovations
Lincoln Center 2
5420 Lyndon B Johnson Fwy
Suite 410
Dallas, TX 75240

Please make checks payable to
Dava Oncology, LP.

Dava Oncology, LP fully complies with
the legal requirements of the ADA and
the rules and regulations thereof. If any
participant in this activity is in need of
accommodations, please notify us in
order to receive service.



Registration fees include refreshment breaks, working lunch, and syllabus materials.

First Name _____ Middle Initial _____ Last Name _____

Credentials: _____ ☐ Physician ☐ Fellow ☐ PA-C ☐ PhD ☐ Pharmacist

Mailing Address _____

Suite _____ City _____ State _____ Postal/Zip Code _____

Phone Number _____ Fax _____

E-mail _____

(your confirmation will be sent via e-mail.)

☐ Check here if you have any special dietary needs, please specify

Please complete the registration form and mail it with your payment to the address below, or
visit www.regonline.com/whistler2015 to register online. Checks and credit cards are accepted.
To register by phone or fax, please call (214) 451-4517 or fax (214) 889-7070 (credit cards only).
Please make checks payable to Dava Oncology, LP. All payments must be made by a draft on a
United States bank.

Choose one of the following options:

Early Registration (ends Feb 6)

☐ MD \$399.00

☐ RN/ PharmD \$299.00

After Feb 6

☐ MD \$499.00

☐ RN/ PharmD \$399.00

Payment can be made by:

☐ Check ☐ VISA ☐ MasterCard ☐ Discover ☐ American Express

Name as It Appears on Credit Card _____

Signature _____

Card Number _____ Expiration Date _____

Security Code _____

(On back [front if American Express] of credit card)

Billing Address of Card (if different from above; zip code required):

Street _____ City _____ State _____ Zip _____

Oncology Meeting Innovations fully complies with the legal requirements of the ADA and the
rules and regulations thereof. If any participant in this activity is in need of accommodations,
please notify us in order to receive service, please call (214) 451-4517.

Please mail payments or inquires to:

Oncology Meeting Innovations
5420 Lyndon B Johnson Fwy
Suite 410
Dallas, TX 75240

Fax: (214) 889-7070

ACCOMMODATIONS

The Fairmont Chateau Whistler is nestled at the base of Blackcomb Mountain, Whistler's landmark ski-in ski-out hotel, that defines mountain luxury. Naturally spectacular, The Fairmont Chateau Whistler resort hotel delivers an ideal setting. This 25-year-old icon will be the location for the March 11-15, 2015 OMI meeting on Lymphoid Malignancies and Multiple Myeloma. Make plans now to attend and secure your reservations early to ensure availability at the Chateau.

We have secured a block of rooms in various categories. This special rate is limited and based on the time of your reservation. The room block will formally close on February 11, 2015. Thus, make your reservations early as this rate is subject to availability.

You have the following options at the following rates (note in Canadian dollars):

- Deluxe Valley View Room \$319 CAD (single or double occupancy)
- Deluxe Slopeside View Room \$359 CAD (single or double occupancy)

AIR TRAVEL

The closest international airport to The Fairmont Chateau Whistler is Vancouver International Airport (YVR). Please note you are required to travel with a valid passport.

GROUND TRANSPORTATION

A JOURNEY AS UNFORGETTABLE AS THE DESTINATION

From rugged coastline to soaring mountain summits, traveling to The Fairmont Chateau Whistler offers every opportunity to marvel at Western Canada's natural beauty.

Alternate transportation options for travel to Whistler include:

- Scheduled motorcoach service
- Rocky Mountaineer (Whistler summer rail service from North Vancouver)
- Float plane
- Helicopter

For assistance in planning your next trip to Whistler, British Columbia, contact the Fairmont Chateau Whistler concierge at 604 938 2006.

The Fairmont Chateau Whistler

**WHISTLER BC,
CANADA**



CONTACT INFORMATION

THE FAIRMONT CHATEAU WHISTLER

4599 Chateau Blvd, Whistler
BC V0N 1B4, Canada

p: +1 604-938-8000

w: <http://www.fairmont.com/whistler>

Two options to make a reservation:

- Reserve online: <https://resweb.passkey.com/go/omi2015>
- Reserve by phone: 1-800-606-8244

Please identify yourself as being with the OMI Global Summit or group code OMIG0315 to receive group rates.